Tagged with P

Korea Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi…

USA 59 novel drugs were approved in the USA in 2018, representing a leap from the 46 approved in 2017 and 22 approved in 2016. 19 of the 59 drugs (32 percent) have been designated ‘first-in-class’ and 34 of the 59 drugs (58 percent) were approved to treat rare or “orphan”…

Spain Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore, he highlights the international strategy and the role the US market will play in the future, as well as his…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…

Opinion Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan’s 2019 Health Care Investor Conference, one of the biggest events in the life sciences calendar and a fantastic indicator of what is to come in healthcare for the year ahead. Here, Crean gives us the inside scoop. …

Canada In total there were 27 new active substances (NASs) approved in Canada in 2018, 18 prescription pharmaceutical drugs and 9 biologics. In terms of companies that saw particular success last year, Merck (MSD outside of the US and Canada) had three prescription drugs approved, as did Swiss-headquartered Vifor Pharma. Global…

Canada The Top 10 bestselling patented medicines in Canada for 2017. Janssen sold CND 938.1 million of its Remicade treatment for gastroenterology, rheumatology and dermatology indications, making up a full 5.6% of all patented medicine sales in Canada. In second place was Abbvie’s Humira with CND 701.9 million of sales and…

Korea Examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Here, Eugene Kim, Seoul office leader of executive search firm Egon Zehnder outlines the new profile he looks for in potential candidates for country manager positions in South…

Spain Sergio Rodriguez, CEO of Pfizer Spain, highlights the strength of the affiliate and the importance for the company in Europe, as well as the key areas that are driving their growth. Furthermore, he gives an overview of the need for innovative companies to partner with key stakeholders and illustrates what…

Spain Within the past decade, Spain has developed into a top player in the European clinical trial network. The pharmaceutical industry has been increasing its investment commitment in the market and taking advantage of the country’s outstanding public health system. These activities are being well received by the government, so much…

Spain Dr Juan Abarca Cidón, president of HM Hospitales, one of Spain’s leading private health groups, gives insight into the private health sector of the country, its relation to the public system, and the opportunities that exist to interact. Dr Abarca goes on to discuss the R&D capabilities of the group…

Spain Damaso Molero, general manager of 3P Biopharmaceuticals, a leading Spanish CDMO, highlights the growth of the company and the need to continuously increase capacity to meet market demands. Furthermore, he touches on the innovation ecosystem in Spain and how 3P works with clients, rather than for them, to achieve long-term…